Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Allopurinol use is associated with lower risk for chronic kidney disease (CKD) among patients with gout and normal baseline kidney function, according to a JAMA Internal Medicine study.
Using a U.K. primary care database, researchers matched roughly 4800 users of allopurinol (at least 300 mg/day) to nonusers. All patients were newly diagnosed with gout and didn't have CKD (stage 3 or higher) at baseline.
During 4–5 median years' follow-up, fewer people taking allopurinol were diagnosed with stage 3 or higher CKD than people not taking the drug (579 vs. 623). Lower doses did not yield a similar effect.
Commentators note: "The important message from this new study ... is that allopurinol is unlikely to contribute to progression of CKD; indeed, it might even be protective, presumably by reducing the risk of urate nephropathy."
Meanwhile, the authors write: "Clinicians should consider evaluating other factors when faced with renal function decline in their patients with gout rather than lowering the dose of or discontinuing allopurinol, a strategy that has contributed to the ongoing suboptimal treatment of gout."
Comment
LINK(S):
JAMA Internal Medicine article (Free)
JAMA Internal Medicine invited commentary (Free)
Background: NEJM Journal Watch General Medicine coverage of allopurinol dose escalation (Your NEJM Journal Watch registration required)